Biosimilars: A Value Proposition

Research output: Contribution to journalArticleResearch

16 Citations (Web of Science)


© 2019, Springer Nature Switzerland AG. Biosimilars are biological agents that effectively replicate original reference products. The main driver of their development is the promise of bringing competition into the marketplace, and consequently contributing to the sustainability of healthcare systems. By reducing financial barriers to biological therapies, biosimilars play a part in budgetary redistribution and, hence, in increasing patients’ access to treatment. They also foster innovation and deliver other non-price-driven advantages. However, the market is such that harmonization of pricing of reference biologics and biosimilars may dissuade physicians from prescribing biosimilars and often creates an unfavorable market environment for the launch of biosimilars. Such dynamics result in a high cost by denying patients the full benefits and added value inherent in biosimilar agents. A more equitable offering of established original biologics and biosimilars is needed to ensure the viability of current healthcare services.
Original languageEnglish
Pages (from-to)353-356
Number of pages4
Publication statusPublished - 1 Aug 2019


  • Biosimilar Pharmaceuticals/economics
  • Costs and Cost Analysis
  • Drug Approval
  • Europe
  • Government Agencies
  • Marketing
  • Registries/statistics & numerical data


Dive into the research topics of 'Biosimilars: A Value Proposition'. Together they form a unique fingerprint.

Cite this